

Prof. Dr. med. habil. Michael Fröhner
 Chefarzt der Klinik für Urologie
 Zeisigwaldklinikum Bethanien Chemnitz
 Zeisigwaldstraße 101
 09130 Chemnitz

17. April 2020

PUBLIKATIONEN

	Publikationen als Erstautor	Publikationen als Koautor	Impactfaktor als Erstautor	Impactfaktor als Koautor
Originalarbeiten:	47	50	164.636	155.768
Kasuistiken:	31	7	87.884	8.859
Letter mit Originaldaten:	19	2	159.254	17.163
Kommentare/Repliken:	39	8	482.402	55.488
Editorial Comments:	8	9	55.403	99.274
Übersichtsarbeiten:	17	26	25.043	46.185
Buchbeiträge:	3	21		
S3-Leitlinien:	-	1		
Patente:	-	5		
Summe:	164	129	975.752	384.707

Hirsch-Index: 22

Kumulativer Impact-Faktor: 1360.459, davon 975.752 als Erstautor

Quelle für Impactfaktor 2015:
 Quelle für Hirsch-Index:

Website <http://admin.webofknowledge.com>
 Website <https://www.scopus.com>

Originalarbeiten

Froehner, M., Koch, R., Hübler, M., Lindner, M., Wirth, M. P., Thomas, C.:
Quantifying the relationship between increasing life expectancy and non-prostate cancer mortality after radical prostatectomy.

Urology 2020 [in press].

Impact-Faktor 2.188

Froehner, M., Koch, R., Heberling, U., Borkowetz, A., Hübler, M., Novotny, V., Wirth, M. P., Thomas, C.:

Validation of a questionnaire-suitable comorbidity index in patients undergoing radical cystectomy

Urol Int 2020 [in press].

Impact-Faktor 1.426

Borkowetz, A., Froehner, M., Rauner, M., Conrad, S., Erdmann, K., Mayr, T., Datta, K., Hofbauer, L., Baretton, G. B., Wirth, M., Fuessel, S., Toma, M., Muders, M. H.:

Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.

Int J Cancer 2019 [Epub ahead of print].

Impact-Faktor 5.085

Hoherück, S., Michler, E., Wunderlich, G., Löck, S., Hölscher, T., Froehner, M., Braune, A., Ivan, P., Seppelt, D., Zöphel, K., Kotzerke, J.:

68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients.

Nuklearmedizin 58:352-362, 2019.

Impact-Faktor 1.352 (2017)

Froehner, M., Muallah, D., Koch, R., Hübler, M., Borkowetz, A., Heberling, U., Huber, J., Wirth, M. P., Thomas, C.:

Socioeconomic status-related parameters as predictors of competing (non-bladder cancer) mortality after radical cystectomy.

Urol Int 2019 [Epub ahead of print].

Impact-Faktor 1.426

Froehner, M., Koch, R., Heberling, U., Hübler, M., Novotny, V., Borkowetz, A., Wirth, M. P., Thomas, C.:

Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy?

World J Urol 2019 [Epub ahead of print].

Impact-Faktor 2.666.

Froehner, M., Koch, R., Farahzadi, S., Heberling, U., Borkowetz, A., Twelker, L., Baretton, G. B., Wirth, M. P., Thomas, C.:

Long-term mortality in patients with positive lymph nodes at the time of radical prostatectomy.

Urol Int 103:427-432, 2019.

Impact-Faktor 1.426

Stasik, S., Salomo, K., Heberling, U., Froehner, M., Sommer, U., Baretton, G. B., Ehninger, G., Wirth, M. P., Thiede, C., Fuessel, S.:

Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Clin Biochem 64:60-63, 2018.
Impact-Faktor 2.382

Thiele, S., Zimmer, A., Göbel, A., Rachner, T. D., Rother, S., Fuessel, S., **Froehner, M.**, Wirth, M. P., Muders, M. H., Baretton, G. B., Jakob, F., Rauner, M., Hofbauer, L. C.:
Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.
Oncotarget 2018;9:27293-27304.
Impact-Faktor 5.008

Zieschang, H., Koch, R., Wirth, M. P., **Froehner, M.:**
Leiomyosarcoma of the urinary bladder in adult patients: A systematic review of the literature and meta-analysis.
Urol Int 102:96–101, 2019.
Impact-Faktor 1.426

Froehner, M., Koch, R., Hübler, M., Heberling, U., Zastrow, S., Novotny, V., Hakenberg, O., Wirth, M. P.:
Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy.
BMC Urol 2018;18:91.
Impact-Faktor 1.413

Borkowetz, A., Renner, T., Platzek, I., Toma, M., Herout, R., Baunacke, M., Groeben, C., Huber, J., Laniado, M., Baretton, G., **Froehner, M.**, Zastrow, S., Wirth, M. P.:
Evaluation of transperineal magnetic resonance imaging/ultrasound-fusion biopsy compared to transrectal systematic biopsy in the prediction of tumour aggressiveness in patients with previously negative biopsy.
Urol Int 102:20-26, 2019.
Impact-Faktor 1.426

Heberling, U., Koch, R., Hübler, M., Baretton, G. B., Hakenberg, O. W., Wirth, M. P., **Froehner, M.:**
Gender and mortality after radical cystectomy: Competing risk analysis.
Urol Int 101:2993-299, 2018.
Impact-Faktor 1.426

Froehner, M., Koch, R., Hübler, M., Renner, T., Borkowetz, A., Zastrow, S., Wirth, M. P.:
Only <10% of patients selected for radical prostatectomy reach the competing mortality rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
Eur Urol Focus 5:361-364, 2019.
Impact-Faktor -

Borkowetz, A., Renner, T., Platzek, I., Toma, M., Herout, R., Baunacke, M., Groeben, C., Huber, J., Laniado, M., Baretton, G. B., **Froehner, M.**, Zastrow, S., Wirth, M. P.:
Evaluation of MRI/ultrasound-fusion biopsy in patients with low-risk prostate cancer under active surveillance undergoing surveillance biopsy.
Urol Int 100:155-163, 2018.
Impact-Faktor 1.426

Herout, R., Graff, J., Borkowetz, A., Zastrow, S., Leike, S., Koch, R., Draeger, D. L., Protzel, C., Hakenberg, O. W., Wirth, M. P., **Froehner, M.:**
Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival.
Urol Oncol 36:11.e1-11.e6, 2018.
Impact-Faktor 2.768

Borkowetz, A., Hadaschik, B., Platzek, I., Toma, M., Torsev, G., Renner, T., Herout, R., Baunacke, M., Laniado, M., Baretton, G., Radtke, J. P., Kesch, C., Hohenfellner, M., **Froehner, M.,** Schlemmer, H. P., Wirth, M., Zastrow S.:
Prospective comparison of transperineal MRI/ultrasound-fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients.
BJU Int 121:53-60, 2017.
Impact-Faktor 3.533

Borkowetz, A., Platzek, I., Toma, M., Renner, T., Herout, R., Baunacke, M., Laniado, M., Baretton, G. B., **Froehner, M.,** Zastrow, S., Wirth, M. P.:
Evaluation of Prostate Imaging Reporting and Data System Classification in the prediction of tumor aggressiveness in targeted magnetic resonance imaging/ultrasound-fusion biopsy.
Urol Int 99:177-185, 2017.
Impact-Faktor 1.426

Froehner, M., Koch, R., Hübler, M., Zastrow, S., Wirth, M. P.:
Predicting competing mortality in patients undergoing radical prostatectomy at an age of 70 years or older.
Eur Urol 71:710-713, 2017.
Impact-Faktor 13.938

Salomo, K., Huebner, D., Boehme, M. U., Herr, A., Brabetz, W., Heberling, U., Hakenberg, O. W., Jahn, D., Grimm M. O., Steinbach, D., Horstmann, M., **Froehner, M.,** Wirth, M. P., Fuessel, S.:
Urinary transcript quantification of CK20 and IGF2 for the non-invasive bladder cancer detection.
J Cancer Res Clin Oncol 143:1757-1769, 2017.
Impact-Faktor 3.141

Froehner, M., Koch, R., Hübler, M., Heberling, U., Novotny, V., Zastrow, S., Baretton, G. B., Wirth, M. P.:
Selection effects may explain smoking-related outcome differences after radical cystectomy.
Eur Urol Focus 4:395-398, 2018.
Impact-Faktor –

Froehner, M., Koch, R., Hübler, M., Heberling, U., Novotny, V., Zastrow, S., Wirth, M. P.:
Validation of the Preoperative Score to Predict Postoperative Mortality (POSPOM) in patients undergoing radical cystectomy.
Eur Urol Focus 5:197-200, 2019.
Impact-Faktor –

Walliczek-Dworschak U, Gudziol V, Mitzschke C, **Froehner M**, Hummel T.
Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes.

Eur Arch Otorhinolaryngol 274:2813-2818, 2017.

Impact-Faktor 1.627

Vetterlein, M. W., Seisen, T., May, M., Nuhne, P., Gierth, M., Mayr, R., Fritsche, H. M., Burger, M., Novotny, V., **Froehner, M.**, Wirth, M. P., Protzel, C., Hakenberg, O. W., Roghmann, F., Palisaari, R. J., Noldus, J., Pycha, A., Bastian, P. J., Trinh, Q. D., Xylinas, E., Shariat, S. F., Rink, M., Chun F. K. H., Dahlem, R., Fisch, M., Aziz, A.:
Effectiveness of adjuvant chemotherapy after radical cystectomy for locally advanced and/or pelvic lymph node-positive muscle-invasive urothelial carcinoma of the bladder: A propensity score-weighted competing risks analysis.

Eur Urol Focus 4:252-259, 2018.

Impact-Faktor -

Froehner, M., Koch, R., Heberling, U., Novotny, V., Hübler, M., Wirth, M. P.:

An easily applicable single condition-based mortality index for patients undergoing radical prostatectomy or radical cystectomy.

Urol Oncol 35:32.e17-32.e23, 2017.

Impact-Faktor 2.768

Froehner, M., Koch, R., Propping, S., Liebeheim, D., Hübler, M., Baretton, G. B., Hakenberg, O. W., Wirth, M. P.:

Level of education and mortality after radical prostatectomy.

Asian J Androl 19:173-177, 2017.

Impact-Faktor 2.596

Froehner, M., Koch, R., Hübler, M., Wirth, M. P.:

Validation of an age-adjusted prostate cancer specific comorbidity index.

Eur Urol 69:764-766, 2016.

Impact-Faktor 13.938

Borkowetz, A., Platzek, I., Toma, M., Renner, T., Herout, R., Baunacke, M., Laniado, M., Baretton, G., **Froehner, M.**, Zastrow, S., Wirth, M.:

Direct comparison of multiparametric MRI and final histopathology in patients with proven prostate cancer in MRI/Ultrasound-fusion biopsy.

BJU Int 118:213-220, 2016.

Impact-Faktor 3.533

Novotny, V.*, **Froehner, M.***, Koch, R., Zastrow, S., Heberling, U., Leike, S., Hübler, M., Wirth, M. P.:

Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90-day mortality after radical cystectomy.

World J Urol 34:1123-1129, 2016.

Impact-Faktor 2.666

*geteilte Erstautorenschaft

Froehner, M., Propping, S., Koch, R., Borkowetz, A., Liebeheim, D., Toma, M., Baretton, G. B., Wirth, M. P.:

Is the post-radical prostatectomy Gleason score a valid predictor of mortality after neoadjuvant hormonal treatment?

Urol Int 96:302-8, 2016.

Impact-Faktor 1.426

Froehner, M., Koch, R., Heberling, U., Novotny, V., Oehlschlaeger, S., Hübler, M., Baretton, G. B., Hakenberg, O. W., Wirth, M. P.:

Decreased overall and bladder cancer-specific mortality with adjuvant chemotherapy after radical cystectomy: multivariable competing risk analysis.

Eur Urol 69:984-987, 2016.

Impact-Faktor 13.938

Novotny, V., **Froehner, M.**, Ollig, J., Koch, R., Zastrow, S., Wirth, M. P.:

Impact of adjuvant intravesical bacillus Calmette-Guérin treatment on patients with high-grade T1 bladder cancer.

Urol Int 96:136-41, 2016.

Impact-Faktor 1.426

Hager, B., Kraywinkel, K., Keck, B., Katalinic, A., Meyer, M., Zeissig, S. R., Stabenow, R., **Froehner, M.**, Huber, J.:

Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011.

Radiother Oncol 115:90-95, 2015.

Impact-Faktor 4.363

Novotny, V., **Froehner, M.**, May, M., Protzel, C., Hergenröther, K., Rink, M., Chun, F. K., Fisch, M., Roghman, F., Palisaar R. J., Noldus, J., Gierth, M., Fritsche, H. M., Burger, M., Sikic, D., Keck, B., Wullich, B., Nuhn, P., Buchner, A., Stief, C. G., Vallo, S., Bartsch, G., Haferkamp, A., Bastian P. J., Hakenberg, O. W., Propping, S., Aziz, A.:

Risk stratification for prediction of locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder.

World J Urol 33:1753-1761, 2015.

Impact-Faktor 2.666

Froehner, M., Koch, R., Novotny, V., Heberling, U., Propping, S., Litz, R. J., Hübler, M., Baretton, G. B., Hakenberg, O. W., Wirth, M. P.:

Lee mortality index as comorbidity measure in patients undergoing radical cystectomy.

SpringerPlus 4:55, 2015.

Impact-Faktor: -

Borkowetz, A., Platzek, I., Toma, M., Laniado, M., Baretton, G., **Froehner, M.**, Koch, R., Wirth, M., Zastrow, S.:

Comparison of systematic transrectal biopsy to transperineal MRI/ultrasound-fusion biopsy for the diagnosis of prostate cancer.

BJU Int 116:873-879, 2015.

Impact-Faktor 3.533

Aziz, A., Shariat, S. F., Roghmann, F., Brookman-May, S., Stief, C. G., Rink, M., Chun, F., Fisch, M., Novotny, V., **Froehner, M.**, Wirth, M. P., Schnabel, M., Fritsche, H. M., Burger, M., Pycha, A., Brisuda, A., Babjuk, M., Vallo, S., Haferkamp, A., Roigas, J., Noldus, J., Stredele, R., Volkmer, B., Bastian, P. J., Xylinas, E., May, M.:

Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder – development of a tool for clinical decision-making.

BJU Int 117:272-279, 2016.

Impact-Faktor 3.533

Thiele, S., Göbel, A., Rachner, T. D., Fuessel, S., **Froehner, M.**, Muders, M. H., Baretton, G. B., Bernhardt, R., Jakob, F., Glüer, C. C., Bornhäuser, M., Rauner, M., Hofbauer, L. C.:

WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo.

J Bone Miner Res 30:471-480, 2015.

Impact-Faktor 6.832

Rachner, T. D., Thiele, S., Göbel, A., Browne, A., Fuessel, S., Erdmann, K., Wirth, M. P., **Fröhner, M.**, Todenhöfer, T., Muders, M. H., Kieslinger, M., Rauner, M., Hofbauer, L.C.:

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients.

BMC Cancer 2014;14:649.

Impact-Faktor 3.362

Martin, N. E., Massey, L., Stowell, C., Bangma, C., Briganti, A., Bill-Axelsson, A., Blute, M., Catto, J., Chen, R., D'Amico, A. V., Feick, G., Fitzpatrick, J., Frank, S., **Froehner, M.**, Frydenberg, M., Glaser, A., Graefen, M., Hamstra, D., Kibel, A., Mendenhall, N., Moretti, K., Ramon, J., Roos, I., Sandler, H., Sullivan, F., Swanson, D., Tewari, A., Vickers, A., Wiegel, T., Huland, H.:

Defining a standard set of patient-centered outcomes for men with localized prostate cancer.

Eur Urol 67:460-677, 2015.

Impact-Faktor 13.938

Froehner, M., Novotny, V., Heberling, U., Rutsch, L., Koch, R., Litz, R. J., Hübler, M., Baretton, G. B., Wirth, M. P.:

Relationship between the number of removed lymph nodes and bladder cancer and competing mortality after radical cystectomy.

Eur Urol 66:987-990, 2014.

Impact-Faktor 13.938

Froehner, M., Koch, R., Hübler, M., Litz, R. J., Wirth, M. P.:

Testing of a novel easy-to-use mortality index in a radical prostatectomy cohort.

Urology 84:307-313, 2014.

Impact-Faktor 2.188

Fröhner, M., Khan, C., Koch, R., Schorr, S. G., Wirth, M.:

Implementierung der S3-Leitlinie Prostatakarzinom im klinischen Alltag: Ergebnisse einer Umfrage unter Urologen.

Urologe 53:1500-3, 2014.

Impact-Faktor 0.444

Froehner, M., Kellner, A. E., Koch, R., Baretton, G. B., Hakenberg, O. W., Wirth, M. P.:

A combined index to classify prognostic comorbidity in candidates for radical prostatectomy.

BMC Urol 14:28, 2014.

Impact-Faktor 1.413

Al-Janabi, O., Taubert, H., Lohse-Fischer, A., **Froehner, M.**, Wach, S., Stoehr, R., Keck, B., Burger, M., Wieland, W. F., Erdmann, K., Wirth, M., Wullich, B., Baretton, G., Magdolen, V., Kotzsch, M., Fuessel, S.:

Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

BioMed Res Int 2014:972587, 2014.

Impact-Faktor 1.579

Erdmann, K., Kaulke, K., Thomae, C., Huebner, D., Sergon, M., **Froehner, M.**, Wirth, M. P., Fuessel, S.:

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs.

BMC Cancer 14:82, 2014.

Impact-Faktor 3.362

Froehner, M., Koch, R., Wirth, M. P., Adam, M., Schlomm, T., Huland, H., Graefen, M.:

Does increasing life expectancy effect competing mortality after radical prostatectomy? Urol Oncol 32:413-8, 2014.

Impact-Faktor 2.768

Froehner, M., Koch, R., Lossnitzer, A., Schober, R. R., Schuler, M., Wirth, M. P.:

Adult inguinoscrotal sarcomas: Outcome analysis of 21 cases, systematic review of the literature and meta-analysis.

World J Urol 32:445-451, 2014.

Impact-Faktor 2.666

Dornbusch, J., Zacharis, A., Meinhardt, M., Erdmann, K., Wolff, I., **Froehner, M.**, Wirth, M. P., Zastrow, S., Fuessel, S.:

Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.

PLoS One 8:e76386, 2013.

Impact-Faktor 3.234

Kunze, D., Erdmann, K., **Froehner, M.**, Wirth, M. P., Fuessel, S.:

Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.

Int J Mol Sci 14:12297-12312, 2013.

Impact Factor: 2.862

Froehner, M., Koch, R., Wirth, M. P.:

Comorbidity and survival of patients selected for radical prostatectomy at an age of 75 years or older.

Asian J Androl 15:667-671, 2013.

Impact-Faktor 2.596

Froehner, M., Novotny, V., Koch, R., Leike, S., Twelker, L., Wirth, M. P.:
 Perioperative complications after radical prostatectomy: open versus robot-assisted laparoscopic approach.
 Urol Int 90:312-315, 2013.
 Impact-Faktor 1.426

Novotny, V., Hakenberg, O. W., **Froehner, M.,** Zastrow, S., Leike, S., Koch, R., Wirth, M. P.:
 Systematic assessment of complications and outcome of radical cystectomy undertaken with curative intent in patients with comorbidity and over 75 years of age.
 Urol Int 90:195-201, 2013.
 Impact-Faktor 1.426

Froehner, M., Hentschel, C., Koch, R., Litz, R. J., Hakenberg, O. W., Wirth, M. P.:
 Which comorbidity classification best fits elderly candidates for radical prostatectomy?
 Urol Oncol 31:461-472, 2013.
 Impact-Faktor 2.768

Froehner, M., Koch, R., Leike, S., Novotny, V., Twelker, L., Wirth, M. P.:
 Urinary tract-related quality of life after radical prostatectomy: open retropubic versus robot-assisted laparoscopic approach.
 Urol Int 90:36-40, 2013.
 Impact-Faktor 1.426

Froehner, M., Scholz, A., Koch, R., Hakenberg, O. W., Baretton, G. B., Wirth, M. P.:
 Competing mortality contributes to excess mortality in patients with poor risk lymph node positive prostate cancer treated with radical prostatectomy.
 Urol Int 89:148-154, 2012.
 Impact-Faktor 1.426

Kunze, D., Erdmann, K., **Froehner, M.,** Wirth, M. P., Fuessel, S.:
 siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells.
 Anticancer Res 32:4313-4318, 2012.
 Impact-Faktor 1.826

Kunze, D., Kraemer, K., Erdmann, K., **Froehner, M.,** Wirth, M. P., Fuessel, S.:
 Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells.
 Int J Oncol 41:1271-1277, 2012.
 Impact-Faktor 3.025

Froehner, M., Schober, R. R., Koch, R., Lossnitzer, A., Laniado, M., Wirth, M. P.:
 Adult urological sarcoma: experience during 2 decades.
 Urol Oncol 31:985-989, 2013.
 Impact-Faktor 2.768

Froehner, M., Koch, R., Litz, R. J., Hakenberg, O. W., Wirth, M. P.:
 Which patients are at the highest risk of dying from competing causes within 10 years after radical prostatectomy?
 BJU Int 110:206-210, 2012.
 Impact-Faktor 3.533

Oehlschläger, S., Fuessel, S., Meye, A., Herrmann, J., Lotzkat, U., **Froehner, M.**, Albrecht, S., Wirth, M. P.:

Importance of erythrocyte band III anion transporter (SLC4A1) on oxalate clearance of calcium oxalate monohydrate stone-forming patients vs. normal controls.

Urology 77:250.e1-5, 2011.

Impact-Faktor 2.188

Froehner, M., Koch, R., Litz, R. J., Hakenberg, O. W., Oehlschlaeger, S., Wirth, M. P.:

Survival analysis in men undergoing radical prostatectomy at an age of 70 years or older.

Urol Oncol 28:628-634, 2010.

Impact-Faktor 2.768

Toma, M. I., Friedrich, K., Meyer, W. D., **Fröhner, M.**, Schneider, S., Wirth, M., Baretton, G. B.:

Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer.

Anal Quant Cytol Histol 32:1-10, 2010.

Impact-Faktor 0.488

Froehner, M., Koch, R., Hakenberg, O. W., Wirth, M. P.:

Second cancers as competing causes of death after radical prostatectomy.

J Urol 182:967-970, 2009.

Impact-Faktor 4.471

Froehner, M., Buck, L. M., Koch, R., Hakenberg, O. W., Wirth, M. P.:

Derivatives of prostate-specific antigen as predictors of incidental prostate cancer.

BJU Int 104:25-28, 2009.

Impact-Faktor 3.533

Froehner, M., Koch, R., Litz, R. J., Wirth, M. P.:

Nomogram underestimates 10-year survival in healthy men selected for radical prostatectomy at age 70 years or older.

Urology 73:610-613, 2009.

Impact-Faktor 2.188

Beyer, J., Wessela, S., Hakenberg, O. W., Kuhlisch, E., Halbritter, K., **Froehner, M.**, Wirth, M. P., Schellong, S. M.:

Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery.

J Thromb Haemost 7:597-604, 2009.

Impact-Faktor 5.720

Oehlschlaeger, S., Fuessel, S., Meye, A., Herrmann, J., **Froehner, M.**, Albrecht, S., Wirth, M. P.:

Role of cellular oxalate in oxalate clearance of calcium oxalate monohydrate stone formers and normal controls.

Urology 73:480-483, 2009.

Impact-Faktor 2.188

Froehner, M., Koch, R., Litz, R. J., Oehlschlaeger, S., Twelker, L., Hakenberg, O. W., Wirth, M. P.:

Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy.

Urology 72:1252-1257, 2008.

Impact-Faktor 2.188

Oehlschlaeger, S., Hakenberg, O. W., **Froehner, M.,** Wirth, M. P.:

Age-related changes of urine calcium excretion after extracorporeal shock wave lithotripsy due to artificial renal calcium leakage.

Urol Int 81:206-209, 2008.

Impact-Faktor 1.426

Froehner, M., Koch, R., Litz, R. J., Hakenberg, O. W., Oehlschlaeger, S., Wirth, M. P.:
Interaction between age and comorbidity as predictors of mortality after radical prostatectomy.

J Urol 179:1823-1829, 2008.

Impact-Faktor 4.471

Froehner, M., Aikele, P., Beuthien-Baumann, B., Kittner, T., Oehlschlaeger, S., Wirth, M. P.:

Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors.

Urol Oncol 25:201-206, 2007.

Impact-Faktor 2.768

Froehner, M., Garbrecht, B., Hakenberg, O. W., Koch, R., Litz, R. J., Oehlschlaeger, S., Twelker, L., Wirth, M. P.:

Changing comorbidity classification patterns at radical prostatectomy during a 10-year period.

Urol Oncol 25:26-31, 2007.

Impact-Faktor 2.768

Schmidt, U., Fuessel, S., Koch, R., Baretton, G. B., Lohse, A., Tomasetti, S., Unversucht, S., **Froehner, M.,** Wirth, M. P., Meye, A.:

Quantitative multi-gene expression profiling of primary prostate cancer.

Prostate 66:1521-1534, 2006.

Impact-Faktor 3.565

Hakenberg, O. W., Nippgen, J. B., **Froehner, M.,** Zastrow, S., Wirth, M. P.:

Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma.

BJU Int 98:1225-1227, 2006.

Impact-Faktor 3.533

Froehner, M., Koch, R., Litz, R. J., Hakenberg, O. W., Oehlschlaeger, S., Wirth, M. P.:
Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age.

Urology 68:583-586, 2006.

Impact-Faktor 2.188

Berdjis, N., Hakenberg, O. W., Novotny, V., **Froehner, M.,** Wirth, M.P.:

Treating renal cell cancer in the elderly.

BJU Int 97:703-705, 2006.

Impact-Faktor 3.533

Froehner, M., Hakenberg, O. W., Koch, R., Schmidt, U., Meye, A., Wirth, M. P.:
Comparison of the clinical value of complexed PSA and total PSA in the discrimination
between benign prostatic hyperplasia and prostate cancer.

Urol Int 76:27-30, 2006.

Impact-Faktor 1.426

Froehner, M., Koch, R., Litz, R. J., Haase, M., Klenk, U., Oehlschlaeger, S., Baretton,
G. B., Wirth, M. P.:

Comparison of tumor- and comorbidity-related predictors of mortality after radical
prostatectomy.

Scand J Urol Nephrol 39:449-454, 2005.

Impact-Faktor 1.243

Froehner, M., Koch, R., Litz, R. J., Oehlschlaeger, S., Hakenberg, O. W., Wirth, M. P.:
Feasibility and limitations of comorbidity measurement in patients undergoing radical
prostatectomy.

Eur Urol 47:190-195, 2005.

Impact-Faktor 13.938

Hakenberg, O. W., Fuessel, S., Richter, K., **Froehner, M.,** Oehlschlaeger, S., Rathert,
P., Meye, A., Wirth, M. P.:

Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments
compared with voided urine cytology in diagnosis of bladder carcinoma.

Urology 64:1121-1126, 2004.

Impact-Faktor 2.188

Schmidt, U., Bilkenroth, U., Linne, C., Fuessel, S., Kraemer, K., **Froehner, M.,** Wirth,
M. P., Meye, A.:

Quantification of disseminated tumor cells in the bloodstream of patients with hormone-
refractory prostate carcinoma undergoing cytotoxic chemotherapy.

Int J Oncol 24:1393-1399, 2004.

Impact-Faktor 3.025

Froehner, M., Koch, R., Litz, R., Oehlschlaeger, S., Wirth, M. P.:

Which conditions contributing to the Charlson score predict survival after radical
prostatectomy?

J Urol 171:697-699, 2004.

Impact-Faktor 4.471

Wirth, M. P., Weissbach, L., Marx, F. J., Heckl, W., Jellinghaus, W., Riedmiller, H.,
Noack, B., Hinke, A., **Froehner, M.:**

Prospective randomized trial comparing flutamide as adjuvant treatment versus
observation after radical prostatectomy for locally advanced, lymph node-negative
prostate cancer.

Eur Urol 45:267-270, 2004.

Impact-Faktor 13.938

Froehner, M., Koch, R., Litz, R., Heller, A., Oehlschlaeger, S., Wirth, M. P.:

Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy.
Urology 62:698-701, 2003.
Impact-Faktor 2.188

Oehlschläger, S., Hakenberg, O. W., **Froehner, M.**, Manseck, A., Wirth, M. P.:
Evaluation of chemical composition of urinary calculi by conventional radiography.
J Endourol 17:810-815, 2003.
Impact-Faktor 1.708

Oehlschläger, S., Albrecht, S., Hakenberg, O. W., Schrödter, S., **Froehner, M.**,
Manseck, A., Wirth, M. P.:
Early changes of oxalate and calcium urine excretion in those with calcium oxalate
stone formation after extracorporeal shock wave lithotripsy.
Urology 62:17-21, 2003.
Impact-Faktor 2.188

Froehner, M., Koch, R., Litz, R., Oehlschlaeger, S., Noack, B., Manseck, A., Albrecht,
D. M., Wirth, M. P.:
Preoperative cardiopulmonary risk assessment as predictor of early non-cancer and
overall mortality after radical prostatectomy.
Urology 61:596-600, 2003.
Impact-Faktor 2.188

Oehlschlaeger, S., Albrecht, S., Hakenberg, O. W., Schrödter, S., **Froehner, M.**,
Manseck, A., Wirth, M. P.:
Clinical impact of the measurement of free radicals and nitric oxide to identify the
reperfusion injury in human renal transplantation.
Transplantation Proc 35:843-844, 2003.
Impact-Faktor 0.982

Oehlschläger, S., Albrecht, S., Hakenberg, O. W., Manseck, A., **Froehner, M.**,
Zimmermann, T., Wirth, M. P.:
Measurement of free radicals and NO by chemiluminescence to identify the reperfusion
injury in renal transplantation.
Luminescence 17:130-132, 2001.
Impact-Faktor 1.518

Froehner, M., Litz, R., Manseck, A., Hakenberg, O. W., Leike, S., Albrecht, D. M.,
Wirth, M. P.:
Relationship of comorbidity, age and perioperative complications in patients undergoing
radical prostatectomy.
Urol Int 67:283-288, 2001.
Impact-Faktor 1.426

Manseck, A., **Fröhner, M.**, Guhr, K., Hakenberg, O., Wirth, M.:
Ist die systematische Biopsie der Transitionalzone zusätzlich zur Sextantenbiopsie der
Prostata sinnvoll?
Aktuel Urol 32:368-371, 2001.
Impact-Faktor 0.162

Manseck, A., Guhr, K., **Froehner, M.**, Hakenberg, O. W., Wirth, M. P.:

Morbidity and discomfort of ten-core biopsy of the prostate evaluated by questionnaire.
Urol Int 66:197-200, 2001.
Impact-Faktor 1.426

Hakenberg, O., Franke, H. J., **Froehner, M.**, Wirth, M. P.:
The treatment of primary urethral carcinoma - the dilemmas of a rare condition:
experience with partial urethrectomy and adjuvant chemotherapy.
Onkologie 24:48-52, 2001.
Impact-Faktor 0.863

Froehner, M., Lossnitzer, A., Manseck, A., Koch, R., Noack, B., Wirth, M. P.:
Favorable long-term outcome in adult genitourinary low-grade sarcoma.
Urology 56:373-377, 2000.
Impact-Faktor 2.188

Hakenberg, O. W., Franke, P., **Froehner, M.**, Manseck, A., Wirth, M. P.:
The value of conventional urine cytology in the diagnosis of residual tumour after
transurethral resection of bladder carcinomas.
Onkologie 23:252-257, 2000.
Impact-Faktor 0.863

Manseck, A., **Froehner, M.**, Oehlschlaeger, S., Hakenberg, O., Friedrich, K., Theissig,
F., Wirth, M. P.:
Is systematic sextant biopsy suitable for the detection of clinically significant prostate
cancer?
Urol Int 65:80-83, 2000.
Impact-Faktor 1.426

Baumann, E., Linß, W., **Fröhner, M.**, Stoya, G., Richter, W.:
pH-induced denaturation of spectrin changes the interaction of membrane proteins in
erythrocyte ghosts. Biochemical and electron microscopic evidence.
Ann Anatomy 176:93-99, 1994.
Impact-Faktor 1.483

Letters to the Editor mit Originaldaten

Froehner, M., Koch, R., Thomas, C.:
Re: Tosoian JJ, Mamawala M, Epstein JI, Landis P, Macura KJ, Simopoulos DN, Carter
HB, Gorin MA. Active surveillance of grade group 1 prostate cancer: Long-term
outcomes from a large prospective cohort. Eur Urol 2020 [Epub ahead of print].
Eur Urol 2020 [in press].
Impact-Faktor 13.938

Froehner, M., Koch, R., Thomas, C.:
Re: External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims
Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
J Urol 2020;203:420.
Impact-Faktor 4.471

Froehner, M., Koch, R., Thomas, C.:

Re: Gandaglia G, Albers P, Abrahamsson PA, et al. Structured population-based prostate-specific antigen screening for prostate cancer: The European Association of Urology position in 2019. *Eur Urol* 2019;76:142-150.

Eur Urol 77:e30, 2020.

Impact-Faktor 13.938

Froehner, M., Koch, R., Wirth, M. P.:

Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer.

Eur Urol 69:e130, 2016.

Impact-Faktor 13.938

Froehner, M., Koch, R., Wirth, M. P.:

Re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting life expectancy in men diagnosed with prostate cancer.

Eur Urol 69:e128, 2016.

Impact-Faktor 13.938

Froehner, M., Koch, R., Wirth, M. P.:

Re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy.

Eur Urol 68:e103, 2015.

Impact-Faktor 13.938

Froehner, M., Koch, R., Wirth, M. P.:

Re: Syed Johar Raza, Timothy Wilson, James O. Peabody, et al. Long-term oncologic outcomes following robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium.

Eur Urol 68:e109, 2015.

Impact-Faktor 13.938

Fröhner, M., Koch, R., Wirth, M.:

Adjuvante Hormontherapie beim lymphknotenpositiven Prostatakarzinom.

Aktuel Urol 46:12-13, 2015.

Impact-Faktor 0.162

Froehner, M., Koch, R., Wirth, M. P.:

Charlson score and competing mortality.

Cancer 120:4003, 2014.

Impact-Faktor 4.889

Froehner, M., Novotny, V., Wirth, M. P., Aziz, A., Brookman-May, S., May, M.:

External validation of a model to predict local failure after radical cystectomy.

Cancer 120:3584, 2014.

Impact-Faktor 4.889

Putz, J., **Froehner, M.,** Wirth, M. P., Jahn, S.:

Androgen receptor-positive renal cell carcinoma.

Urology 84:734-735, 2014.

Impact-Faktor 2.188

Novotny, V., Wirth, M. P., **Froehner, M.:**

Comorbidity and 90-day mortality.

Eur Urol 66:e13, 2014.

Impact-Faktor 13.938

Froehner, M., Koch, R., Wirth, M. P.:

Age and Charlson score.

Ann Surg Oncol 2014 [<http://www.surgonc.org/news-publications/annals-of-surgical-oncology/letters-to-the-editor/age-and-charlson-score>].

Impact-Faktor 3.930

Froehner, M., Koch, R., Wirth, M. P.:

Re: Immediate hormonal treatment versus treatment after biochemical failure.

Eur Urol 65:e24, 2014.

Impact-Faktor 13.938

Froehner, M., Koch, R., Wirth, M. P.:

Re: Effect of age, tumor risk, and comorbidity in a U.S. Population-based cohort of men with prostate cancer.

Ann Intern Med 159:370, 2013.

Impact-Faktor 17.810

Froehner, M., Koch, R., Wirth, M. P.:

Comorbidity and mortality after brachytherapy.

Int J Radiat Oncol Biol Phys 87:431; 2013.

Impact-Faktor 4.258

Froehner, M., Koch, R., Wirth, M. P.:

Re: American Society of Anesthesiologists (ASA) classification as predictor of survival after radical cystectomy.

Eur Urol 63:e9, 2013.

Impact-Faktor 13.938

Froehner, M., Koch, R., Wirth, M. P.:

Comorbidities, treatment and survival.

J Gen Intern Med 27:1240, 2012.

Impact-Faktor 3.449

Froehner, M., Koch, R., Wirth, M. P.:

Overtreatment of men with low-risk prostate cancer and significant comorbidity.

Cancer 117:4805, 2011.

Impact-Faktor 4.889

Froehner, M., Koch, R., Litz, R. J., Wirth, M. P.:

Re: Guzzo et al.: Prediction of mortality after radical prostatectomy by Charlson comorbidity index.

Urology 76:1522, 2010.

Impact-Faktor 2.188

Froehner, M., Koch, R., Litz, R. J., Wirth, M. P.:

Cardiovascular disease and prostate cancer-specific mortality.

Int J Radiat Oncol Biol Phys 76:1274, 2010.
Impact-Faktor 4.258

Kasuistiken

Froehner, M., Jahn, S., Plodeck, V., Laniado, M., Wirth, M. P.:
Chronically infected urachal remnant mimicking tumor with peritoneal carcinomatosis.
Urology 116:e3-e4, 2018.
Impact-Faktor 2.188

Excessive β -human chorionic gonadotropin elevation in a patient with inguinoscrotal liposarcoma
Sarcoma Res Int 4:1042, 2017.
Impact-Faktor -

Froehner, M., Schaab, F., Hofmockel, T., Hoffmann, R. T., Fahlenkamp, D., Wirth, M. P.:
Delayed radiographic manifestation of renal pseudoaneurysms after blunt trauma.
Urology 103:e9-e10, 2017.
Impact-Faktor 2.188

Froehner, M., Toma, M., Zöphel, K., Novotny, V., Laniado, M., Wirth, M. P.:
PSMA-PET/CT-positive Paget disease in a patient with newly diagnosed prostate cancer: Imaging and bone biopsy findings.
Case Rep Urol 2017;2017:1654231.
Impact-Faktor -

Froehner, M., Kuithan, F., Zöphel, K., Heberling, U., Laniado, M., Wirth, M. P.:
Prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography and immunohistochemical findings in a patient with synchronous metastatic penile and prostate cancer.
Urology 101:e5-e6, 2016.
Impact-Faktor 2.188

Froehner, M., Meinhardt, M., K., Parmentier, S., Hugo, C., Wirth, M. P.:
Renal sarcoidosis mimicking xanthogranulomatous pyelonephritis.
Urology 97:e19-e20, 2016.
Impact-Faktor 2.188

Froehner, M., Zöphel, K., Höscher, T., Laniado, M., Wirth, M. P.:
Splenuculus masquerading as prostate-specific membrane antigen-positive lymph node metastasis in a patient with prostate-specific antigen relapse after radical prostatectomy.
Urology 94:e1-2, 2016.
Impact-Faktor 2.188

Froehner, M., Heberling, U., Zastrow, S., Toma, M., Wirth, M. P.:
[Growth of a level III vena cava tumor thrombus within one month.](#)
Urology 90:e1-2, 2016.
Impact-Faktor 2.188

Heberling, U., **Fröhner, M.**, Oehlschlaeger, S., Wirth, M. P.:
 Superglue in the urethra: surgical treatment.
 Urol Int 96:119-121, 2016.
 Impact-Faktor 1.426

Baunacke, M., Toma, M., Novotny, V., **Fröhner, M.**, Wirth, M., Huber, J.:
 Inzidentelles undifferenziertes Karzinom der Prostata
 Urologe 54:1602-1605, 2015.
 Impact-Faktor 0.444

Froehner, M., Abolmaali, N., Wirth, M. P.:
 Prostate-specific-antigen-negative prostate cancer recurrence?
 Urology 2013;81:e17-8.
 Impact-Faktor 2.188

Froehner, M., Bethke, A., Wirth, M. P.:
 A young woman with severe sepsis.
 BJU Int (Website), 2010.
 [<http://www.bjui.org/ContentFullItem.aspx?id=673&SectionType=1&title=A-young>].
 Impact-Faktor 3.533

Golgor, E., Stroszczyński, C., **Froehner, M.**:
 Extraperitoneal inguinoscrotal herniation of the ureter: a rare case of recurrence after
 hernia repair.
 Urol Int 83:113-115, 2009.
 Impact-Faktor 1.426

Zastrow, S., **Froehner, M.**, Platzek, I., Novotny, V., Wirth, M. P.:
 Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.
 Urology 73:868-870, 2009.
 Impact-Faktor 2.188

Froehner, M., Passauer, J., Schuler, U., Hakenberg, O. W., Wirth, M. P.:
 Successful chemotherapy for advanced non-seminomatous germ cell tumor in a patient
 undergoing chronic hemodialysis.
 J Clin Oncol 25:1282-1284, 2007.
 Impact-Faktor 18.428

Froehner, M., Beuthien-Baumann, B., Dittert, D. D., Schuler, U., Wirth, M. P.:
 Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.
 Cancer Chemother Pharmacol 58:716-718, 2006.
 Impact-Faktor 2.769

Froehner, M., Beuthien-Baumann, B., Wirth, M. P.:
¹¹C-Acetate positron emission tomography for occult prostate cancer.
 Urol Oncol 24:410-411, 2006.
 Impact-Faktor 2.768

Schrödter, S., Hakenberg, O., Oehlschläger, S., **Fröhner, M.**, Kittner, T., Wirth, M.:
 Akute Nierenkolik aufgrund einer ventrikuloperitonealen Shunt-Metastase eines
 intrakraniellen Germinoms.
 Aktuel Urol 37:141-142, 2006.

Impact-Faktor 0.162

Froehner, M., Aikele, P., Wirth, M. P.:

Renal staghorn calculus?

Urology 65:171, 2005.

Impact-Faktor 2.188

Froehner, M., Ockert, D., Aust D. E., Wirth, M. P., Saeger, H. D.:

Gastrointestinal stromal tumor presenting as a scrotal mass.

Int J Urol 11:445-447, 2004.

Impact-Faktor 2.409

Froehner, M., Haase, M., Hakenberg, O. W., Wirth, M. P.:

Urinary immunocytology for primary bladder B-cell lymphoma.

Urology 63:381-383, 2004.

Impact-Faktor 2.188

Froehner, M., Bartholdt, E., Meye, A., Manseck, A., Wirth, M. P.:

Adult prostate sarcoma diagnosed from tissue spontaneously excreted through the urethra.

Urol Oncol 22:119-120, 2004.

Impact-Faktor 2.768

Froehner, M., Theissig, F., Konopke, R., Saeger, H. D., Ockert, D.:

Malignant fibrous histiocytoma masquerading as germ cell tumor by producing β -human chorionic gonadotropin and neuron-specific enolase.

Urology 62:551, 2003.

Impact-Faktor 2.188

Oehlschläger, S., Lossnitzer, A., **Froehner, M.**, Hakenberg, O. W., Manseck, A., Wirth, M. P.:

Distal ureteral stenosis after early adjuvant intravesical mitomycin C application for superficial bladder cancer.

Urol Int 70:74-76, 2003.

Impact-Faktor 1.426

Froehner, M., Lossnitzer, A., Wirth, M. P.:

Cavernous hemangioma of the spermatic cord - ultrasonographic appearance.

BJU Int 88:644, 2001.

Impact-Faktor 3.533

Froehner, M., Gaertner, H. J., Manseck, A., Wirth, M. P.:

Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year old man.

Urology 58:799, 2001.

Impact-Faktor 2.188

Froehner, M., Ockert, D., Bunk, A., Saeger, H. D.:

Liposarcoma of the diaphragm: CT and sonographic appearances.

Abdom Imaging 26:300-302, 2001.

Impact-Faktor 1.630

Froehner, M., Gaertner, H. J., Hakenberg, O. W., Wirth, M. P.:
 Malignant fibrous histiocytoma of the ileum at a site of previous surgery.
 Surg Today 31:242-245, 2001.
 Impact-Faktor 1.526

Froehner, M., Gaertner, H. J., Manseck, A., Oehlschlaeger, S., Wirth, M. P.:
 Retroperitoneal leiomyosarcoma associated with an elevated β -HCG serum level
 mimicking extragonadal germ cell tumor.
 Sarcoma 4:179-181, 2000.
 Impact-Faktor -

Froehner, M., Schöbl, R., Wirth, M. P.:
 Mucoepidermoid penile carcinoma – clinical, histological and immunohistochemical
 characterization of an uncommon neoplasm.
 Urology 56:154, 2000.
 Impact-Faktor 2.188

Hakenberg, O. W., **Froehner, M., Wirth, M. P.:**
 Symptomatic paraurethral corpus spongiosum cyst in a male patient.
 Urology 55:590, 2000.
 Impact-Faktor 2.188

Froehner, M., Hanisch, U., Noack, B., Hakenberg, O. W., Wirth, M. P.:
 Ossifying cavernous hemangioma masquerading as adrenal tuberculosis.
 J Urol 163:894-895, 2000.
 Impact-Faktor 4.471

Froehner, M., Fischer, R., Leike, S., Hakenberg, O. W., Noack, B., Wirth, M. P.:
 Intratesticular leiomyosarcoma in a young man after high-dose doping with Oral-
 Turinabol: A case report.
 Cancer 86:1582-1586, 1999.
 Impact-Faktor 4.889

Froehner, M., Manseck, A., Haase, M., Hakenberg, O. W., Wirth, M. P.:
 Locally recurrent malignant fibrous histiocytoma: a rare and aggressive genitourinary
 malignancy.
 Urol Int 62:164-170, 1999.
 Impact-Faktor 1.426

Froehner, M., Hakenberg, O. W., Manseck, A., Oehlschlaeger, S., Wirth, M. P.:
 Unusual semi-spheric perivesical calcification after pelvic radiotherapy.
 Urol Int 62:122-123, 1999.
 Impact-Faktor 1.426

Froehner, M., Tsatalpas, P., Wirth, M. P.:
 Giant penile cavernous hemangioma with intrapelvic extension.
 Urology 52:414-415, 1999.
 Impact-Faktor 2.188

Froehner, M., Manseck, A., Lossnitzer, A., Wirth, M. P.:
 Late local and pulmonary recurrence of renal cell carcinoma.
 Urol Int 60:248-250, 1998.

Impact-Faktor 1.426

Froehner, M., Leike, S., Manseck, A., Haase, M., Wirth, M. P.:
Splenuculus mimicking late local recurrence of renal cell carcinoma.
Scand J Urol Nephrol 32:418-419, 1998.

Impact-Faktor 1.243

Kommentare und Repliken

Fröhner, M., Wirth, M.:

Prostatakarzinom: Langzeitdaten zeigen Vorteile durch die radikale Operation.
Dtsch Med Wochenschr 144:858-859, 2019.
Impact-Faktor 0.503

Froehner, M., Thomas, C.:

Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.
Eur Urol 76:e75, 2019.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:

Androgen deprivation therapy and Alzheimer's disease.
J Clin Oncol 34:2801, 2016.
Impact-Faktor 18.428

Fröhner, M., Wirth, M. P.:

Nutzen der adjuvanten Chemotherapie.
Urologie Scan 3:16-17, 2016
Impact-Faktor -

Froehner, M., Wirth, M. P.:

Re: Wallis CJ, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK. Surgery versus radiotherapy for clinically-localized prostate cancer: A systematic review and meta-analysis.
Eur Urol 70:e9, 2016.
Impact-Faktor 13.938

Wirth, M. P., **Froehner, M.:**

Author reply.
J Urol 195:803, 2016.
Impact-Faktor 4.471

Froehner, M., Wirth, M. P.:

Enzalutamide in metastatic prostate cancer before chemotherapy.
N Engl J Med 371:1755, 2014.
Impact-Faktor 55.873

Froehner, M., Wirth, M. P.:

Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
Eur Urol. In press.
Eur Urol 67:e112, 2015.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:

Re: Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.

BMJ 2014: <http://www.bmj.com/content/348/bmj.g1502/rr/694008>
Impact-Faktor 17.445

Froehner, M., Koch, R., Hübler, M., Litz, R. J., Wirth, M. P.:
Reply.
Urology 84:312-313, 2014.
Impact-Faktor 2.188

Froehner, M., Wirth, M. P.:
Re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control.
Eur Urol 66:e85, 2014.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:
Socio-economic deprivation and cancer survival in Germany.
Int J Cancer 135:1989, 2014
Impact-Faktor 5.085

Wirth, M. P., **Froehner, M.:**
Words of Wisdom: Re: Early Detection of Prostate Cancer: AUA Guideline.
Eur Urol 65:1218, 2014.
Impact-Faktor 13.938

Froehner, M.:
Comorbidity and mortality.
Eur Urol 65:e41, 2014.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:
Re: Robot-assisted vs. open radical prostatectomy: The differential effect of regionalization, procedure volume and operative approach.
J Urol 190:1440-1441, 2013.
Impact-Faktor 4.471

Froehner, M.:
Screening and efficacy of radical prostatectomy.
Asian J Androl 15:441-442, 2013.
Impact-Faktor 2.596

Froehner, M., Wirth, M. P.:
Re: Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy.
Eur Urol 63:e38, 2013.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:
Age and survival benefit.
Eur Urol 62:e53, 2012.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:

Re: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials.
Eur Urol 62:350, 2012.
Impact-Faktor 13.938

Froehner, M.:

Prostate cancer and competing mortality after radical prostatectomy or observation.
Eur Urol 61:e11, 2012.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:

Early prostate cancer - treat or watch?
N Engl J Med 365:568, 2011.
Impact-Faktor 55.873

Froehner, M., Wirth, M. P.:

Cabazitaxel for castration-resistant prostate cancer.
Lancet 377:121-122, 2011.
Impact-Faktor 45.217

Froehner, M.:

Prostate cancer-specific survival in elderly patients.
J Clin Oncol 29:e281, 2011.
Impact-Faktor 18.428

Froehner, M.:

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cancer 117:2577, 2011.
Impact-Faktor 4.889

Wirth, M. P., Froehner, M.:

Re: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Eur Urol 58:939-940, 2010.
Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:

Secondary malignancies after treatment for prostate cancer.
Int J Radiat Oncol Biol Phys 78:1279, 2010.
Impact-Faktor 4.258

Wirth, M., Weißflog, C., Fröhner, M.:

Positiver Einfluß auf Progress und Langzeitüberleben.
Aktuel Urol 41:290-292, 2010.
Impact-Faktor 0.162

Froehner, M.:

Age and prostate cancer survival.
JAMA 303:33-34, 2010.
Impact-Faktor 35.289

Wirth, M., Fröhner, M.:

Finasterid reduziert Risiko abhängig vom Gleason-Score
 Aktuel Urol 41:1, 2010.
 Impact-Faktor 0.162

Froehner, M., Koch, R., Hakenberg, O. W., Wirth, M. P.:

Reply by authors.
 J Urol 182:971, 2009.
 Impact-Faktor 4.471

Fröhner, M., Wirth, M.:

Studie nicht verallgemeinerbar.
 Aktuel Urol 40:136, 2009.
 Impact-Faktor 0.162

Froehner, M., Koch, R., Litz, R. J. , Wirth, M. P.:

Reply.
 Urology 73:614, 2009.
 Impact-Faktor 2.188

Froehner, M.:

Malignant epithelioid renal angiomyolipoma involving the inferior vena cava in a patient with tuberous sclerosis.
 Urol Int 80:104, 2008.
 Impact-Faktor 1.426

Froehner, M.:

Peripheral primitive neuroectodermal tumor arising from the seminal vesicle.
 Urol Int 80:216, 2008.
 Impact-Faktor 1.426

Froehner, M., Koch, R., Litz, R. J., Hakenberg, O. W., Oehlschlaeger, S., Wirth, M. P.:

Reply by authors.
 J Urol 179:1823-1829, 2008.
 Impact-Faktor 4.471

Froehner, M.:

Life expectancy estimation by nomogram.
 J Clin Oncol 26:690, 2008.
 Impact-Faktor 18.428

Fröhner, M.:

Kommentar zur Studie: Einfluß von Monotherapien des lokalisierten Prostatakarzinoms auf die gesundheitsbezogene Lebensqualität.
 Aktuel Urol 39:98-99, 2008.
 Impact-Faktor 0.162

Froehner, M.:

Clinical comment on: Androgen-independent prostate cancer treated with resection of the solitary metastatic site.
 Urol Int 79:373, 2007.
 Impact-Faktor 1.426

Froehner, M.:

Clinical comment on: Proptosis – an uncommon presentation of orbital metastases secondary to prostate cancer.

Urol Int 79:375, 2007.

Impact-Faktor 1.426

Wirth, M., Fröhner, M.:

Kommentar zur Studie: Androgenentzugstherapie erhöht das Frakturrisiko.

Aktuel Urol 36:298-300, 2005.

Impact-Faktor 0.162

Froehner, M., Koch, R., Litz, R. J., Oehlschlaeger, S., Hakenberg, O. W., Wirth, M. P.:

Author reply.

Eur Urol 48:168-169, 2005.

Impact-Faktor 13.938

Froehner, M., Koch, R., Litz, R. J., Oehlschlaeger, S., Hakenberg, O. W., Wirth, M. P.:

Author reply.

Eur Urol 48:170, 2005.

Impact-Faktor 13.938

Wirth, M. P., Weissbach, L., Marx, F. J., Heckl, W., Jellinghaus, W., Riedmiller, H., Noack, B., Hinke, A., Froehner, M.:

Author reply.

Eur Urol 46:273, 2004.

Impact-Faktor 13.938

Froehner, M.:

Re: High-grade urinary bladder leiomyosarcoma in adults.

Urology 64:188, 2004.

Impact-Faktor 2.188

Wirth, M., Fröhner, M., Hausmann, R.:

Kommentar zur Studie: Zoledronsäure erhöht Knochendichte.

Aktuel Urol 34:424, 2003.

Impact-Faktor 0.162

Froehner, M.:

Re: Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension.

J Urol 170:1954, 2003.

Impact-Faktor 4.471

Froehner, M., Fischer, R., Wirth, M. P.:

Author reply.

Cancer 88:2196-2197, 2000.

Impact-Faktor 4.889

Editorials/Editorial Comments

Froehner, M., Wirth, M. P.:

Adjuvant radiotherapy and mortality in lymph node-positive prostate cancer.
AME Medical Journal 3:31, 2018.

Impact-Faktor -

Fröhner, M., Rübben, H:

Geriatrisches Assessment.
Urologe 54:1699-700, 2015.

Impact-Faktor 0.444

Wirth, M. P., **Froehner, M.:**

Should the urologist treat castration resistant prostate cancer?: Yes.
J Urol 194:286, 2015.

Impact-Faktor 4.471

Wirth, M. P., **Froehner, M.:**

Prostate-specific antigen pox virus vaccination for recurrent prostate cancer.
Eur Urol 68:372-323, 2015.

Impact-Faktor 13.938

Wirth, M., **Fröhner, M.:**

Minimal-invasive vs. offen-chirurgische Verfahren in der Therapie des
Prostatakarzinoms.

Urologe 54:210-212, 2015.

Impact-Faktor 0.444

Wirth, M. P., **Froehner, M.:**

Simultaneous targeting of the Akt and androgen receptor pathways.
Eur Urol 67:991-2, 2015.

Impact-Faktor 13.938

Froehner, M., Wirth, M. P.:

Approaches to radical prostatectomy
J Comp Eff Res 3:451-453, 2014.

Impact-Faktor: 0.719

Wirth, M. P., **Froehner, M.:**

Radical prostatectomy at young age.
BJU Int 114:4-5, 2014.

Impact-Faktor 3.533

Wirth, M. P., **Froehner, M.:**

Predictive significance of confirmation biopsies in patients on active surveillance.
Eur Urol 66: 414–415, 2014.

Impact-Faktor 13.938

Froehner, M.:

Editorial Comment.
J Urol 188:802, 2012.
Impact-Faktor 4.471

Wirth, M. P., **Froehner, M.:**

Impact factor for ranking academic urologic institutions.
Eur Urol 61:440-441, 2012.
Impact-Faktor 13.938

Froehner, M.:

Editorial Comment.
J Urol 185:839, 2011.
Impact-Faktor 4.471

Wirth, M. P., **Froehner, M.:**

Radical prostatectomy only centers – the future in genitourinary surgery?
Eur Urol 57:953-954, 2010.
Impact-Faktor 13.938

Wirth, M. P., **Froehner, M.:**

Robot-assisted radical prostatectomy – the new gold standard?
Eur Urol 57:750-751, 2010.
Impact-Faktor 13.938

Froehner, M.:

Editorial Comment on: Molecular lymph node staging in bladder urothelial carcinoma: Impact on survival.
Eur Urol 54:1371, 2008.
Impact-Faktor 13.938

Froehner, M.:

Editorial Comment on: Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0µg per liter.
Eur Urol 54:368-369, 2008.
Impact-Faktor 13.938

Froehner, M.:

Editorial Comment on: Prostate cancer nomograms – an update.
Eur Urol 50:926, 2006.
Impact-Faktor 13.938

Übersichtsarbeiten

Williams, S. B., Kamat, A. M., Chaime K., **Froehner, M.**, Wirth, M. P., Wiklund, P. N., Black, P. C., Steinberg, G. D., Boorjian, S. A., Daneshmand, S., Goebell, P. J., Kamal, P. S., Shariat, S.F., Thalmann, G. N.:
Systematic review on comorbidity and competing risk assessment among bladder cancer patients.
Eur Urol Oncol 1:91-100, 2018.

Impact-Faktor -

Fröhner, M., Wirth, M.:
Metastasen Chirurgie beim Prostatakarzinom
Urologe 56:1017-1018, 2017.
Impact-Faktor 0.444

Fröhner, M., Wirth, M.:
Therapie des Prostatakarzinoms: Profitieren auch ältere Patienten?
Allgemeinarzt 39:16-18, 2017.
Impact-Faktor -

Fröhner, M., Wirth, M.:
Urologische Notfälle in der klinischen Praxis.
Allgemeinarzt 15/2016:16-22, 2016.
Impact-Faktor -

Fröhner, M., Wirth, M.:
Welche Änderungen sind für die dritte Aktualisierung der S3-Leitlinie zu erwarten?
Uro-News 19(9):41-42, 2015.
Impact-Faktor -

Fröhner, M.:
Komorbidität als Meßparameter in der Urologie.
Uro-News 19(7-8):21-23, 2015.
Impact-Faktor -

Fröhner, M., Rübgen, H.:
Behandlung des Harnblasenkarzinoms im Alter.
Urologe 54:510-515, 2015.
Impact-Faktor 0.444

Froehner, M., Hölscher, T., Hakenberg, O. W., Wirth, M. P.:
Treatment of bone metastases in urologic malignancies.
Urol Int 93:249-256, 2014.
Impact-Faktor 1.426

Fröhner, M., Wirth, M.:
Organ- und Funktionserhalt beim Prostatakarzinom.
Urologe 53:1295-1301, 2014.
Impact-Faktor 0.444

Fröhner, M.:
Komorbiditätsindex nach Charlson.
Uro-News 17:39-41, 2013.
Impact-Faktor -

Froehner, M., Wirth, M. P.:
Locally advanced prostate cancer: Optimal therapy in older patients.
Drugs Aging 30:959-967, 2013.
Impact-Faktor 2.838

Fröhner, M., Wirth, M.:

Alter und Komorbidität beim frühen Prostatakarzinom.

Urologe 51:1356-1361, 2012.

Impact-Faktor 0.444

Wirth, M., **Fröhner, M.:**

S3-Leitlinie zur Diagnostik und Therapie des Prostatakarzinoms. Aktualisierung.

Onkologe 18:355-364, 2012.

Impact-Faktor 0.136

Froehner, M., Rosenberg, M. T.:

Does prostate cancer aggressiveness change with increasing age?

Int J Clin Pract 65:521-523, 2011.

Impact-Faktor 2.566

Graefen, M., **Fröhner, M.,** Wirth, M.:

PSA zur Therapiesteuerung.

Urologe 50:309-312, 2011.

Impact-Faktor 0.444

Wirth, M., **Fröhner, M.:**

Früherkennung beim Prostatakarzinom: Pro und Contra.

Sachs Arztebl 22:221-222, 2011.

Impact-Faktor -

Rosenberg, M. T., **Froehner, M.,** Albala, D., Miner, M. M.:

Biology and natural history of prostate cancer and the role of chemoprevention.

Int J Clin Pract 64:1746-1753, 2010.

Impact-Faktor 2.566

Grimm, M. O., Wolff, I., Zastrow, S., **Fröhner, M.,** Wirth, M.:

Advances in renal cell carcinoma treatment.

Ther Adv Urol 2:11-17, 2010.

Impact-Faktor -

Grimm, M. O., Thomas, C., **Fröhner, M.,** Wiegel, T., Heidenreich, A., Thüroff, J. W.,
Wirth, M.:

Pelvine Lymphadenektomie und radikale Prostatektomie. Empfehlungen der S3-Leitlinie.

Urologe 49:206-210, 2010.

Impact-Faktor 0.444

Wirth, M. P., **Froehner, M.:**

Impact of age, comorbidity and tumor biology on treatment decision in prostate cancer.

AUA News 15(4): 18-19, 2010.

Impact-Faktor -

Fröhner, M., Grimm, M. O. Wirth, M.:

Medikamentöse Therapie des Prostatakarzinoms. Zusammenfassung und Kommentierung der Empfehlungen der interdisziplinären S3-Leitlinie zur Früherkennung, Diagnose und Therapie des Prostatakarzinoms.

Krankenhauspharmazie 31:133-140, 2010.

Impact-Faktor -

Froehner, M., Brausi, M. A., Herr, H. W., Muto, G., Studer, U. E.:
Complications following radical cystectomy for bladder cancer in the elderly.
Eur Urol 56:443-454, 2009.
Impact-Faktor 13.938

Wirth, M. P., **Froehner, M.:**
The timing of radiation therapy for margin positive disease after radical prostatectomy:
Late (temporarily delayed) treatment.
AUA News 14(8):8-11, 2009.
Impact-Faktor -

Wirth, M. P., Hakenberg, O. W., **Froehner, M.:**
Adjuvant hormonal treatment - The Bicalutamide Early Prostate Cancer Program.
Front Radiat Ther Oncol 41:39-48, 2008.
Impact-Faktor -

Fröhner, M., Wirth, M.:
Früherkennung des Prostatakrebses.
Onkologie 14:142-146, 2008.
Impact-Faktor 0.136

Froehner, M., Hakenberg, O. W., Wirth, M. P.:
Molecular therapy in urologic oncology.
Urol Int 79:1-7, 2007.
Impact-Faktor 1.426

Wirth, M. P., Hakenberg, O. W., **Froehner, M.:**
Optimal treatment of locally advanced prostate cancer.
World J Urol 25:169-176, 2007.
Impact-Faktor 2.666

Wirth, M. P., **Froehner, M.:**
Lymph node disease after radical prostatectomy.
Minerva Urol Nefrol 59:53-57, 2007.
Impact-Faktor 0.965

Wirth, M. P., Hakenberg, O. W., **Froehner, M.:**
Antiandrogens in the treatment of prostate cancer.
Eur Urol 51:306-314, 2007.
Impact-Faktor 13.938

Hakenberg, O. W., **Fröhner, M.**, Wirth, M. P.:
Treatment of locally advanced prostate cancer - the case for radical prostatectomy.
Urol Int 77:193-199, 2006.
Impact-Faktor 1.426

Wirth, M., Hakenberg, O., **Fröhner, M.:**
Therapie des lokal fortgeschrittenen Prostatakarzinoms.
Urologe 44:1295-1302, 2005.
Impact-Faktor 0.444

Wirth, M., Fröhner, M.:

Bedeutung von Komorbidität und Alter bei der radikalen Prostatektomie.

Urologe 43:935-941, 2004.

Impact-Faktor 0.444

Wirth, M. P., Froehner, M.:

Adjuvant hormonal treatment for prostate cancer: the Bicalutamide Early Prostate Cancer Program.

Oncology (Basel) 65 (suppl. 1):1-4, 2003.

Impact-Faktor 2.422

Wirth, M. P., Froehner, M.:

Value of endocrine therapy for early and locally advanced prostate cancer.

Drugs Aging 20:115-124, 2003.

Impact-Faktor 2.838

Wirth, M. P., Froehner, M.:

The management of localised or locally advanced prostate cancer.

Am J Cancer 1:387-396, 2002.

Impact-Faktor -

Wirth, M. P., Froehner, M.:

Perspectives in adjuvant treatment of prostate cancer.

Urol Int 85:1-5, 2002.

Impact-Faktor 1.426

Froehner, M., Wirth, M. P.:

Etiologic factors in soft tissue sarcomas.

Onkologie 24:139-142, 2001.

Impact-Faktor 0.863

Manseck, A., Froehner, M., Oehlschlaeger, S., Wirth, M. P.:

Prostate cancer in the elderly.

Eur J Ger 4:211-215, 2000.

Impact-Faktor -

Wirth, M., Fröhner, M.:

Diagnostik und individualisierte Therapie des lokoregionären Prostatakarzinoms.

Urologe [A] 39:578-587, 2000.

Impact-Faktor 0.444

Wirth, M. P., Froehner, M.:

Comorbidity in prostate cancer.

Aging Male 3:132-136, 2000.

Impact-Faktor 2.000

Wirth, M., Fröhner, M.:

PSA-Anstieg nach radikaler Prostatektomie.

Urologe [A] 39:3-8, 2000.

Impact-Faktor 0.444

Wirth, M., **Fröhner, M.:**
Seltene urologische Tumoren.
Onkologie 5:956-962, 1999.
Impact-Faktor 0.136

Wirth M., **Froehner M.:**
A review of studies of hormonal adjuvant therapy in prostate cancer.
Eur Urol 36 (suppl. 2):14-19, 1999.
Impact-Faktor 13.938

Buchbeiträge

Wirth, M., **Fröhner, M.:**
Prostatakarzinom.
In: Domschke, W., Berger, M., Hohenberger, W., Meinertz, T., Possinger, K. (Hrsg.):
Therapiehandbuch, 6. Auflage. Elsevier Urban und Fischer München, 2015 [im Druck].
ISBN-13: nicht bekannt.

Wirth, M., **Fröhner, M.:**
Prostatakarzinom: Epidemiologie, Ätiologie, Prävention und Früherkennung/Screening.
In: Michel., S. M., Thüroff, J. W., Janetschek, G., Wirth, M.: Die Urologie, Band II.
Springer Medizin Verlag Berlin Heidelberg, S. 1301-1304, 2016.
ISBN-13: 978-3-642-39939-8

Wirth, M., **Fröhner, M.**, Platzek, I., Laniado, M., Kotzerke, J.:
Prostatakarzinom: Diagnostik.
In: Michel., S. M., Thüroff, J. W., Janetschek, G., Wirth, M.: Die Urologie, Band II.
Springer Medizin Verlag Berlin Heidelberg, S. 1305-1320, 2016.
ISBN-13: 978-3-642-39939-8

Wirth, M., **Fröhner, M.**, Baumann, M., Hölscher, T.:
Prostatakarzinom: Kurative Therapie.
In: Michel., S. M., Thüroff, J. W., Janetschek, G., Wirth, M.: Die Urologie, Band II.
Springer Medizin Verlag Berlin Heidelberg, S. 1341-1362, 2016.
ISBN-13: 978-3-642-39939-8

Huber, J., Brogsitter, C., Kotzerke, J., Hölscher, T., Baumann, M., **Fröhner, M.**, Wirth,
M.:
Prostatakarzinom: Palliative Therapie.
In: Michel., S. M., Thüroff, J. W., Janetschek, G., Wirth, M.: Die Urologie, Band II.
Springer Medizin Verlag Berlin Heidelberg, S. 1363-1384, 2016.
ISBN-13: 978-3-642-39939-8

Wirth, M., **Fröhner, M.:**
Seltene Prostatatumoren.
In: Michel., S. M., Thüroff, J. W., Janetschek, G., Wirth, M.: Die Urologie, Band II.
Springer Medizin Verlag Berlin Heidelberg, S. 1385-1388, 2016.
ISBN-13: 978-3-642-39939-8

Wirth, M., Fröhner, M.:

Seltene Samenblasentumoren.

In: Michel., S. M., Thüroff, J. W., Janetschek, G., Wirth, M.: Die Urologie, Band II. Springer Medizin Verlag Berlin Heidelberg, S. 1389-1390, 2016.

ISBN-13: 978-3-642-39939-8

Fröhner, M., Wirth, M.:

Komorbidität in der geriatrischen Urologie.

In: Michel., S. M., Thüroff, J. W., Janetschek, G., Wirth, M.: Die Urologie, Band II. Springer Medizin Verlag Berlin Heidelberg, S. 2261-2271, 2016.

ISBN-13: 978-3-642-39939-8

Froehner, M.:

Pyelonephritis.

In: Merseburger, A. S., Kuczyk, M. A., Moul, J. W. (eds.): Urology at a glance. Springer Medizin Verlag Heidelberg, S. 219-223, 2014.

ISBN-13: 978-3-642-54859-8

Wirth, M., Fröhner, M.:

Therapie des lokal begrenzten Prostatakarzinoms.

In: Rübben, H. (Hrsg.): *Uroonkologie*, 6. Auflage. Springer Medizin Verlag Heidelberg, S. 537-551, 2012.

ISBN-13: 978-3-642-01381-2

Wirth, M., Fröhner, M.:

Prostatakarzinom.

In: Domschke, W., Berger, M., Hohenberger, W., Meinertz, T., Possinger, K. (Hrsg.): *Therapiehandbuch*, 5. Auflage. Elsevier Urban und Fischer München, J 18, 1-4, 2011.

ISBN-13: nicht bekannt.

Wirth, M., Fröhner, M.:

Urogenitale Tumoren.

In: Siewert, J. R., Rothmund, M., Schumpelick, V. (Hrsg.): *Praxis der Visceralchirurgie, Onkologische Chirurgie*, 3. Auflage. Springer Medizin Verlag Heidelberg, S. 841-861, 2010.

ISBN-13: 978-3642038075

Wirth, M., Fröhner, M.:

Therapie des lokal begrenzten Prostatakarzinoms.

In: Rübben, H. (Hrsg.): *Uroonkologie*, 5. Auflage. Springer Medizin Verlag Heidelberg, S. 537-555, 2009.

ISBN-13: 978-3642013812

Wirth, M., Fröhner, M.:

Hormontherapie des Prostatakarzinoms.

In: Ehninger, G. (Hrsg.): *Dresdner Symposium Hämatologie und Onkologie 2008*, Lukon Verlagsgesellschaft mbH München, S. 98-103, 2009.

ISBN: 978-3—933012-12-8

Wirth, M., Fröhner, M.:

Therapie des lokal begrenzten und lokal fortgeschrittenen Prostatakarzinoms.

In: Jocham, D., Miller, K. (Hrsg.): *Praxis der Urologie, Band II*. Thieme Verlag, S. 155-163, 2007.
ISBN-13: 978-3131260031

Wirth, M., Fröhner, M.:

PSA-Anstieg nach kurativer Therapie.

In: Jocham, D., Miller, K. (Hrsg.): *Praxis der Urologie, Band II*. Thieme Verlag, S. 164-165, 2007.
ISBN-13: 978-3131260031

Wirth, M., Hakenberg, O., Fröhner, M.:

Therapie des lokal begrenzten Prostatakarzinoms.

In: Rübben, H. (Hrsg.): *Uroonkologie*, 4. Auflage. Springer Medizin Verlag Heidelberg, S. 429-445, 2007.
ISBN-13: 978-3642013812

Froehner, M., Wirth, M. P.:

Epidemiology and etiologic factors of malignant soft tissue tumors.

In: Liberman, A. P. (ed.): *Progress in AIDS Research*. Nova Science, New York, pp. 81-107, 2005.

Wirth, M. P., Froehner, M.:

The role of endocrine treatment in the management of prostate cancer.

In: Lucas, N. J. (ed.): *Prostate Cancer*. Nova Science, New York, pp. 217-238, 2004.

Wirth, M. P., Froehner, M., Hakenberg, O. W.:

Adjuvant therapy in prostate cancer.

In: Kirby, R., O'Leary M.: *Hot Topics in Urology*. Elsevier Limited, Edinburgh, pp. 127-137, 2004.

Wedding, U., Budach, W., Fröhner, M., Manseck, A., Wirth, M., Höffken, K.:
Prostatakarzinom.

In: Höffken, K., Kolb, G., Wedding, U.: *Geriatrische Onkologie*. Springer, Heidelberg, Berlin, S. 635-661, 2002.

Wirth, M. P., Froehner, M., Hakenberg, O. W.:

Adjuvant and neoadjuvant treatment of prostate cancer.

In: Schröder, F. H.: *Progress and Controversies in Oncological Urology VI*. Parthenon Publishing Group, New York, London, pp. 211-217, 2001.

Wirth, M., Fröhner, M.:

Skelettmetastasierung beim Prostatakarzinom. Therapeutische Möglichkeiten. Erwartungen von der palliativen Schmerztherapie mit Radionukliden.

In Franke, W.-G., Andreeff, M., Heiden, U., Götz, H.-J.: *Nuklearmedizin und Tumorthherapie*. W. Zuckschwerdt Verlag, München, Bern, Wien New York, S. 21-27, 2000.

S3-Leitlinien

Deutsche Gesellschaft für Urologie e. V.:

Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Version 1.01 - Oktober 2009.
Verfügbar unter: <http://www.leitlinien.de/mdb/downloads/dguurologie/prostatakarzinom-lang.pdf>.

1. Aktualisierung der Leitlinie, Version 2012: Verfügbar unter <http://www.awmf.org/leitlinien/detail/ll/043-022OL.html>

2. Aktualisierung der Leitlinie, Version 2014: Verfügbar unter http://leitlinienprogramm-onkologie.de/uploads/tx_sbdownloader/LL_Prostata_Langversion_3.0.pdf.

3. Aktualisierung der Leitlinie, Version 2016: Verfügbar unter http://www.awmf.org/uploads/tx_szleitlinien/043-022OLk_S3_Prostatakarzinom_2016-12.pdf.

4. Aktualisierung der Leitlinie, Version 2017 (Konsultationsfassung): Verfügbar unter http://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostata_5_0/LL_Prostata_Langversion_0_5_0.pdf.

Patente

Horn, F., Hackermüller, J., Christ, S., Reiche, K., Wirth, M., **Fröhner, M.**, Füssel, S.:
Novel RNA-biomarkers for diagnosis and prognosis of prostate carcinoma.
Publiziert am 11. Juni 2015
International Publication Number WO 2015/082418 A1

Horn, F., Hackermüller, J., Christ, S., Reiche, K., Wirth, M., **Fröhner, M.**, Füssel, S.:
Novel RNA-biomarkers for diagnosis of prostate cancer.
Publiziert am 11. Juni 2015
International Publication Number WO 2015/082414 A1

Horn, F., Hackermüller, J., Christ, S., Reiche, K., Wirth, M., **Fröhner, M.**, Füssel, S.:
Novel RNA-biomarkers for diagnosis of prostate cancer.
Publiziert am 11. Juni 2015
International Publication Number WO 2015/082416 A1

Horn, F., Hackermüller, J., Christ, S., Reiche, K., Wirth, M., **Fröhner, M.**, Füssel, S.:
Novel RNA-biomarkers for diagnosis of prostate cancer.
Publiziert am 11. Juni 2015
International Publication Number WO 2015/082417 A1

Horn, F., Hackermüller, J., Christ, S., Reiche, K., Wirth, M., **Fröhner, M.**, Füssel, S.:
Novel RNA-biomarkers for diagnosis of prostate cancer.
Publiziert am 11. Juni 2015
International Publication Number WO 2015/082420 A1